{"id":"W3155830986","doi":"10.1158/1557-3265.radsci21-po-077","title":"Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Clinical endpoint; Prostate cancer; Radionuclide therapy; Oncology; Cabazitaxel; Internal medicine; Hormonal therapy; Docetaxel; Androgen deprivation therapy; Abiraterone acetate; Metastatic breast cancer; Clinical trial; Progression-free survival; Prednisone; Chemotherapy; Cancer; Breast cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005225844,0.002184153,0.002406137,0.0006034873,0.0006251911,0.001321903,0.001518885,0.002127451,0.007928664],"category_scores_gemma":[0.001726208,0.0006087788,0.001910329,0.000534584,0.00168932,0.001491843,0.00059036,0.003888106,0.002558846],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008718246,"about_ca_system_score_gemma":0.003082634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001304775,"about_ca_topic_score_gemma":0.001868449,"domain_scores_codex":[0.9985998,0.0009939389,0.00004947955,0.0001191269,0.00009152268,0.0001460977],"domain_scores_gemma":[0.9980646,0.0004054351,0.0002447777,0.0001719954,0.0001410957,0.000972152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8967024,0.04764533,0.003873138,0.0006852322,0.0009872091,0.0001738437,0.0002034234,0.0009303971,0.01211182,0.0003106985,0.003183312,0.0331932],"study_design_scores_gemma":[0.6776156,0.3154912,0.003405984,0.00002877419,0.0002334503,0.00008387423,0.00003301508,0.0004779939,0.001038372,0.000172271,0.001404384,0.00001497014],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.9773373,0.001646034,0.0009225992,0.001151195,0.0001975548,0.01097098,0.003316775,0.0002164825,0.004241063],"genre_scores_gemma":[0.9519628,0.002225867,0.00522243,0.002569592,0.0004724676,0.01487487,0.01215054,0.0001250575,0.01039639],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.007928664,"threshold_uncertainty_score":0.02763718,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5805525165238268,"score_gpt":0.6232808433027445,"score_spread":0.04272832677891769,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}